false
0002010788
0002010788
2025-06-26
2025-06-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
June
26, 2025
EXOZYMES
INC.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
001-42204 |
|
83-4550057 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
750
Royal Oaks Drive, Suite 106
Monrovia,
CA 91016
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: (626) 415-1488
Check
the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock |
|
EXOZ |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01 — Entry into Material Agreement.
eXoZymes
Inc. (the “Company”) has been selected to participate in the Meta-PURE initiative, a National Science Foundation (“NSF”)
funded project under the CFIRE (Cell-Free Systems Toward Increased Range of Use-Inspired Applications) program aimed at transforming
the scalability and accessibility of cell-free systems to expand real-world applications. The project coalition of partner enterprises
is being led by The Georgia Institute of Technology. Meta-PURE will build a suite of standardized, interoperable ‘modules’
for cell-free biomanufacturing, enabling plug-and-play modules that can rapidly shift between use cases - from high-value nutraceuticals,
to essential chemicals or pharmaceuticals. Meta-PURE is part of the CFIRE program and supported under Cooperative Agreement No. 2452482.
eXoZymes
will serve as the key industrial partner with Meta-PURE, with an approximate $3 million share of the total project award of $9.2
million. The project will commence July 1, 2025, and will run for three years.
eXoZymes
will develop a cell free ATP-generating module - essentially a cell-free power plant - that fuels different chemical production modules
to be developed now and in the future, supporting cell-free manufacturing of several market-relevant targets. eXoZymes’s
technology permits decoupling the power module from the production
module, enabling faster reaction times, greater product yields, and making the development of production modules more accessible for
our coalition partners
across a broad spectrum of synthetic biology applications. The other coalition partners will develop targets spanning a wide range of
complexity and markets, relying on eXoZymes’ plug-and-play cell-free power plant, which will be tested and optimized to both purified
and lysate-based exozymes biosolutions to ensure compatibility and performance.
eXoZymes’
role also includes developing a production module for santalene, an extremely high-value fragrance compound, traditionally extracted
from sandalwood for use in aromatherapy and traditional medicine formulations. Derivates of santalene have been investigated in
pharmaceutical use cases.
| Item
9.01. |
Financial
Statements and Exhibits. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date: |
June
26, 2025 |
EXOZYMES
INC. |
| |
|
|
|
| |
|
By |
/s/
Fouad Nawaz |
| |
|
|
Fouad
Nawaz, |
| |
|
|
Vice
President, Finance |
